오피오이드 유발성 변비 시장 : 활성 성분, 약물 종류, 투여 방법, 유통 채널별 - 세계 예측(2025-2030년)

The Opioid Induced Constipation Market was valued at USD 65.95 million in 2023, expected to reach USD 70.10 million in 2024, and is projected to grow at a CAGR of 6.69%, to USD 103.78 million by 2030.

Opioid Induced Constipation (OIC) is a common side effect among patients using opioid analgesics for pain management, posing a significant area of interest for pharmaceutical companies and healthcare providers. The increasing prevalence of chronic pain and the subsequent rise in opioid consumption drive the necessity for effective OIC management solutions. Key applications include prescription medications, over-the-counter remedies, and non-pharmacological interventions aimed at alleviating constipation symptoms. The end-users span across hospitals, home care settings, and specialty clinics. Key growth influencers include the growing awareness surrounding opioid side effects, advancements in drug formulations, and increased healthcare spending. The latest opportunities lie in personalized medicine approaches, focusing on patient-specific solutions that consider genetic and lifestyle factors influencing constipation. Companies can capitalize on these opportunities by investing in patient education and developing comprehensive OIC management programs. However, market growth faces challenges such as stringent regulatory requirements for new drug approvals, the stigma associated with long-term opioid use, and the complexity of accurately diagnosing OIC versus other types of constipation. Innovation areas ripe for exploration include developing non-opioid pain management solutions that minimize or eliminate the risk of constipation, as well as leveraging digital health tools to monitor and manage symptoms effectively. Research can also be targeted towards understanding the microbiome's role in OIC, offering insights into novel therapeutic targets. Despite these challenges, the global market for OIC therapies is expected to grow as the aging population and incidence of chronic pain increase. Businesses within this niche can enhance market penetration by aligning with evolving regulatory standards, fostering collaborations with healthcare providers, and emphasizing the development of holistic and patient-centric care models that integrate cutting-edge treatment options.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Opioid Induced Constipation Market

The Opioid Induced Constipation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising geriatric population with constipation complications
  • Growing prevalence of kidney disorders
  • Surging availability of diversified treatments
• Market Restraints
  • Stringent approval process and time-consuming
• Market Opportunities
  • Proliferating use of opioids
  • Rise in availability in retail pharmacies
• Market Challenges
  • Concern regarding opioid tolerance and addiction

Porter's Five Forces: A Strategic Tool for Navigating the Opioid Induced Constipation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Opioid Induced Constipation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Opioid Induced Constipation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Opioid Induced Constipation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Opioid Induced Constipation Market

A detailed market share analysis in the Opioid Induced Constipation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Opioid Induced Constipation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Opioid Induced Constipation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Opioid Induced Constipation Market

A strategic analysis of the Opioid Induced Constipation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Opioid Induced Constipation Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ironwood Pharmaceuticals, Inc., Lantheus, Mylan by Viatris Inc., Pfizer, Inc., RedHill Biopharma Inc., Salix Pharmaceuticals by Bausch Health Companies Inc., Shionogo & Co. Ltd., SLA Pharma AG, Synergy Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Opioid Induced Constipation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Active Ingredients, market is studied across Bulk Cathartics, Stimulant Cathartics, Docusate Sodium, Emollient/Lubricant Cathartics, Lubiprostone, Methylnaltrexone Bromide, Naloxegol, Osmotic laxatives, and Prostaglandins/Prokinetic Drugs.
• Based on Drug Class, market is studied across Locally Acting Chloride Channel Activator (LACCA), Non-Selective Opioid Antagonist, Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA), and μ-Opioid Antagonist.
• Based on Mode of Administration, market is studied across Oral and Parenteral.
• Based on Distribution Channel, market is studied across Drug Store, Hospital Pharmacies, and Independent Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising geriatric population with constipation complications
    • 5.1.1.2. Growing prevalence of kidney disorders
    • 5.1.1.3. Surging availability of diversified treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent approval process and time-consuming
  • 5.1.3. Opportunities
    • 5.1.3.1. Proliferating use of opioids
    • 5.1.3.2. Rise in availability in retail pharmacies
  • 5.1.4. Challenges
    • 5.1.4.1. Concern regarding opioid tolerance and addiction
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Opioid Induced Constipation Market, by Active Ingredients

• 6.1. Introduction
• 6.2. Bulk Cathartics, Stimulant Cathartics
• 6.3. Docusate Sodium
• 6.4. Emollient/Lubricant Cathartics
• 6.5. Lubiprostone
• 6.6. Methylnaltrexone Bromide
• 6.7. Naloxegol
• 6.8. Osmotic laxatives
• 6.9. Prostaglandins/Prokinetic Drugs

7. Opioid Induced Constipation Market, by Drug Class

• 7.1. Introduction
• 7.2. Locally Acting Chloride Channel Activator (LACCA)
• 7.3. Non-Selective Opioid Antagonist
• 7.4. Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA)
• 7.5. μ-Opioid Antagonist

8. Opioid Induced Constipation Market, by Mode of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Opioid Induced Constipation Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Drug Store
• 9.3. Hospital Pharmacies
• 9.4. Independent Pharmacies

10. Americas Opioid Induced Constipation Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Opioid Induced Constipation Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Opioid Induced Constipation Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AstraZeneca PLC
• 2. Fresenius Kabi AG
• 3. GlaxoSmithKline PLC
• 4. Hikma Pharmaceuticals PLC
• 5. Ironwood Pharmaceuticals, Inc.
• 6. Lantheus
• 7. Mylan by Viatris Inc.
• 8. Pfizer, Inc.
• 9. RedHill Biopharma Inc.
• 10. Salix Pharmaceuticals by Bausch Health Companies Inc.
• 11. Shionogo & Co. Ltd.
• 12. SLA Pharma AG
• 13. Synergy Pharmaceuticals Inc.
• 14. Takeda Pharmaceutical Company Limited
• 15. Teva Pharmaceutical Industries Ltd.